Dr. Adams noted that certain key treatment risks are reduced or eliminated with the use of MicroPulse, and patient comfort is increased compared to conventional, continuous-wave laser treatment.
"Patient care is about caring for the patient and individualizing treatment, which is why I offer MicroPulse for my AMD and diabetic patients," Dr. Adams said. "It doesn't burn or damage the retina and the results are often excellent…It's really impressive technology."
"Numerous recent studies have shown the effectiveness and durability of the MicroPulse technology in treating DME, meaning it should be considered a cost-effective alternative to the regimen of drug treatments via eye injections currently in use," noted
"Drugs injected directly into the eye have a role in treating retinal diseases, but there are serious issues in terms of costs and logistics due to the need for continuous injections for the rest of one's life. This is just not a sustainable model in today's value-based medicine world," Moore said. "MicroPulse offers powerful advantages, in terms of durability, economics and logistics for payors and patients."
To see the entire program, click on the following link: https://www.dropbox.com/s/tnbasgtsdvhpxgs/Dr%20Adams%2C%20American%20Health%20Front%202014.mp4
The program can also be seen on
https://www.youtube.com/watch?v=6B59WmxzvXY
About MicroPulse Technology
MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.
About
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's products and the markets for the Company's products. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended
Video - http://www.youtube.com/watch?v=6B59WmxzvXY
SOURCE
IRIDEX Contact: Jim Mackaness, CFO & COO, 650-940-4700; Investor Relations Contact: Rene Caron, Allen & Caron, 949-474-4300, rene@allencaron.com